CLINICAL TRIALS AND OBSERVATIONS AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
نویسندگان
چکیده
Giuseppe Avvisati,1 Francesco Lo-Coco,2,3 Francesca Paola Paoloni,4 Maria Concetta Petti,5 Daniela Diverio,6 Marco Vignetti,6 Roberto Latagliata,6 Giorgina Specchia,7 Michele Baccarani,8 Eros Di Bona,9 Giuseppe Fioritoni,10 Filippo Marmont,11 Alessandro Rambaldi,12 Francesco Di Raimondo,13 Maria Grazia Kropp,14 Giovanni Pizzolo,15 Enrico M. Pogliani,16 Giuseppe Rossi,17 Nicola Cantore,18 Francesco Nobile,19 Attilio Gabbas,20 Felicetto Ferrara,21 Paola Fazi,4 Sergio Amadori,2 and Franco Mandelli,4 for the GIMEMA, AIEOP, and EORTC Cooperative Groups
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia
The aim of this study was to determine the efficacy and safety of treatment of pediatric acute promyelocytic leukemia (APL) with single-agent arsenic trioxide (ATO). A total of 19 children (< 15 years of age) with newly diagnosed APL were treated with single-agent ATO for remission induction and postremission therapy. Seventeen of the children (89.5%) achieved complete hematologic remission, an...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid
A novel intravenous liposomal formulation of all-trans retinoic acid (ATRA) was evaluated in 69 patients with acute promyelocytic leukemia (APL): 32 new diagnoses, 35 relapses, and 2 oral ATRA failures. Liposomal ATRA (90 mg/m2) was administered every other day until complete remission (CR) or a maximum of 56 days. Treatment following CR was liposomal ATRA with or without chemotherapy. In an in...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
Arsenic trioxide, as a single agent, has proven efficacy in inducing molecular remission in patients with acute promyelocytic leukemia (APL). There is limited longterm outcome data with single-agent As 2 O3 in the management of newly diagnosed cases of APL. Between January 1998 to December 2004, 72 newly diagnosed cases of APL were treated with a regimen of single-agent As2O3 at our center. Com...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Arsenic trioxide (As2O3) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined. We randomized 481 patients (age > 15 years) with untreated APL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 courses of consolidation th...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
Francesco Lo-Coco,1,2 Giuseppe Avvisati,3 Marco Vignetti,4 Massimo Breccia,4 Eugenio Gallo,5 Alessandro Rambaldi,6 Francesca Paoloni,7 Giuseppe Fioritoni,8 Felicetto Ferrara,9 Giorgina Specchia,10 Giuseppe Cimino,4 Daniela Diverio,4 Erika Borlenghi,11 Giovanni Martinelli,12 Francesco Di Raimondo,13 Eros Di Bona,14 Paola Fazi,7 Antonio Peta,15 Alberto Bosi,16 Angelo M. Carella,17 Francesco Fabbi...
متن کامل